Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Raul Mostoslavsky
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Galilei Biosciences Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Mostoslavsky is a co-founder of Galilei Biosciences Inc. with equity in the private company. Galilei Biosciences Inc. seeks to develop activators of the mammalian SIRT6 protein. The research project investigates the role of SIRT6 in controlling metabolism in colorectal cancer cells, which could provide a putative therapeutic approach to tackle cancer development. The results of the research could therefore be of interest to the company.
The Role of SIRT6 and Metabolism in APC Mediated Tumorigenesis
Colorectal cancer is the third leading cause of cancer morbidity and mortality in the US. One hallmark of cancer cells is their particular metabolism, where sugars are utilized mainly to produce lactate instead of energy through mitochondria (Warburg Effect), with recent studies arguing that such dependency on sugars represents a potential Achilles' heel for tumors. We have found that a protein from the sirtuin deacetylase family, SIRT6, is a critical regulator of energy metabolism, specifically controlling glucose utilization in cells. In this proposal, we will investigate the role of SIRT6 in controlling metaboism in colorectal cancer cells; strikingly, our preliminary results suggest that colon cancer cells rel highly on sugar metabolism, and such a dependency appears to be specifically regulated by SIRT6, providing us in the future with a putative therapeutic approach to tackle metabolism in these oftenly devastating cancers.
Filed on August 28, 2017.
Tell us what you know about Raul Mostoslavsky's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Raul Mostoslavsky filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Raul Mostoslavsky | Massachusetts General Hospital | Conflict of Interest | Galilei Biosciences, Inc. | Value cannot be readily determined |
| Raul Mostoslavsky | Massachusetts General Hospital | Conflict of Interest | Galilei Biosciences Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.